How are GLP-1 drugs impacting hospital finances?

GLP-1 drugs are significantly increasing prescription drug spending for hospital systems, in some cases exceeding inpatient care costs, leading to financial strain and budget deficits.

What measures are being taken to manage GLP-1 drug costs?

Some employers and insurers are requiring patients to undergo diet and lifestyle programs before covering GLP-1 drugs for weight loss, and pharmaceutical companies are exploring price reductions.

Why are GLP-1 drugs causing a financial challenge for healthcare systems?

The high cost and surging demand for GLP-1 medications for weight loss are outpacing the budgets of healthcare systems and insurers, despite their recognized health benefits.

Home / Business and Economy / GLP-1 Drugs Strain Hospital Budgets

GLP-1 Drugs Strain Hospital Budgets

16 Apr

•

Summary

Prescription drug spending now exceeds inpatient care costs.
GLP-1 drug coverage caused a $180 million loss for one insurer.
Some employers now require lifestyle programs before covering weight loss drugs.

The increasing demand for GLP-1 drugs such as Wegovy and Zepbound is placing immense financial pressure on healthcare systems across the United States. Dr. Joseph Cacchione, CEO of Jefferson, reported that his organization's spending on prescription drugs, driven by these weight loss medications, now surpasses its inpatient care expenses.

Jefferson's insurance arm experienced a significant loss of approximately $180 million in 2025, with a substantial portion attributed to GLP-1 coverage. This financial strain led to over 600 employee layoffs. To mitigate these costs, Jefferson's insurance plan implemented a policy requiring employees to engage in diet and lifestyle programs before approving GLP-1s for weight loss, a measure that has already yielded $20 million in savings.